ADAM17 selectively activates the IL-6 trans-signaling/ERK MAPK axis in KRAS-addicted lung cancer.

ADAM17 Protein / antagonists & inhibitors Animals Cell Line, Tumor Genotype Humans Lung Neoplasms / pathology Mice Mitogen-Activated Protein Kinase 1 / metabolism Mitogen-Activated Protein Kinase 3 / metabolism Mutation Phosphorylation Proto-Oncogene Proteins p21(ras) / genetics Receptors, Interleukin-6 / metabolism Signal Transduction p38 Mitogen-Activated Protein Kinases / metabolism
ERK MAPK KRAS ADAM17 IL‐6 trans‐signaling lung adenocarcinoma

Journal

EMBO molecular medicine
ISSN: 1757-4684
Titre abrégé: EMBO Mol Med
Pays: England
ID NLM: 101487380

Informations de publication

Date de publication:
04 2019
Historique:
pubmed: 6 3 2019
medline: 21 4 2020
entrez: 6 3 2019
Statut: ppublish

Résumé

Oncogenic

Identifiants

DOI: 10.15252/emmm.201809976 PMID: 30833304 PMC: PMC6460353
pubmed: 30833304
pii: emmm.201809976
doi: 10.15252/emmm.201809976
pmc: PMC6460353
pii:
doi:

Substances chimiques

Receptors, Interleukin-6 0
Mitogen-Activated Protein Kinase 1 EC 2.7.11.24
Mitogen-Activated Protein Kinase 3 EC 2.7.11.24
p38 Mitogen-Activated Protein Kinases EC 2.7.11.24
ADAM17 Protein EC 3.4.24.86
ADAM17 protein, human EC 3.4.24.86
Proto-Oncogene Proteins p21(ras) EC 3.6.5.2

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Informations de copyright

© 2019 The Authors. Published under the terms of the CC BY 4.0 license.

Références

Clin Cancer Res. 2017 Jun 15;23(12):3012-3024
pubmed: 28039262
JCI Insight. 2016 Aug 18;1(13):
pubmed: 27642633
Nat Rev Immunol. 2018 Dec;18(12):773-789
pubmed: 30254251
Clin Sci (Lond). 2012 Feb;122(4):143-59
pubmed: 22029668
PLoS Biol. 2010 Jun 29;8(6):e1000412
pubmed: 20613859
Sci Rep. 2016 Dec 16;6:35598
pubmed: 27982031
Oncogene. 2006 Mar 30;25(14):2105-12
pubmed: 16288213
Nat Rev Rheumatol. 2017 Jul;13(7):399-409
pubmed: 28615731
Mol Cancer. 2018 Feb 19;17(1):33
pubmed: 29455666
Nat Rev Cancer. 2011 Jan;11(1):59-67
pubmed: 21160526
J Biol Chem. 2015 Nov 6;290(45):26943-53
pubmed: 26363066
Cancer Cell. 2012 Aug 14;22(2):222-34
pubmed: 22897852
Int J Oncol. 2012 May;40(5):1561-8
pubmed: 22266952
Biochim Biophys Acta. 2011 May;1813(5):878-88
pubmed: 21296109
Cancer Cell. 2006 Jul;10(1):39-50
pubmed: 16843264
Cancer. 2001 Sep 15;92(6):1525-30
pubmed: 11745231
Biochem J. 2010 May 13;428(2):293-304
pubmed: 20331435
J Cell Sci. 2005 Jun 1;118(Pt 11):2371-80
pubmed: 15923650
Nature. 2008 Oct 2;455(7213):679-83
pubmed: 18716624
Cancer Cell. 2013 Nov 11;24(5):617-30
pubmed: 24229709
J Clin Oncol. 2013 Jun 10;31(17):2173-81
pubmed: 23630215
Cell. 2018 Jan 25;172(3):578-589.e17
pubmed: 29373830
Cancer Cell. 2004 Apr;5(4):375-87
pubmed: 15093544
Lung Cancer. 2016 Feb;92:29-34
pubmed: 26775593
Mediators Inflamm. 2017;2017:9673537
pubmed: 29230082
Nat Rev Drug Discov. 2014 Nov;13(11):828-51
pubmed: 25323927
Cancer Cell. 2012 Sep 11;22(3):304-17
pubmed: 22975374
Onco Targets Ther. 2018 Oct 24;11:7407-7415
pubmed: 30425528
Nat Rev Drug Discov. 2018 Jun;17(6):395-412
pubmed: 29725131
Cancer Cell. 2018 Feb 12;33(2):217-228.e4
pubmed: 29395869
Nat Protoc. 2009;4(7):1064-72
pubmed: 19561589
Blood. 2017 Jul 27;130(4):514-526
pubmed: 28550040
Eur J Pharm Sci. 2017 Dec 15;110:62-69
pubmed: 28554668
Curr Med Chem. 2018 Feb 13;25(5):558-574
pubmed: 28554329
Biochim Biophys Acta Mol Cell Res. 2017 Nov;1864(11 Pt B):2059-2070
pubmed: 28705384
Lancet. 2014 May 3;383(9928):1561-71
pubmed: 24576776
Clin Cancer Res. 2016 Sep 1;22(17):4428-39
pubmed: 27076628
Mol Med Rep. 2014 May;9(5):1935-40
pubmed: 24626788
Proc Natl Acad Sci U S A. 2014 Apr 1;111(13):4952-7
pubmed: 24586047
Clin Cancer Res. 2018 Mar 15;24(6):1459-1472
pubmed: 29330205
Cancer Res. 2011 Feb 1;71(3):1071-80
pubmed: 21148749
Nat Immunol. 2015 May;16(5):448-57
pubmed: 25898198
Cancer Res. 2012 May 15;72(10):2457-67
pubmed: 22589270
J Exp Med. 2010 Aug 2;207(8):1617-24
pubmed: 20603312
Nat Med. 2016 Mar;22(3):270-7
pubmed: 26855149
Cancer Discov. 2016 Mar;6(3):316-29
pubmed: 26739882
Mol Cancer Ther. 2015 Jul;14(7):1637-49
pubmed: 25948294
Sci Transl Med. 2018 Jul 25;10(451):
pubmed: 30045976
Blood. 1998 Nov 15;92(10):3495-504
pubmed: 9808540
Mol Cancer Ther. 2011 Feb;10(2):336-46
pubmed: 21306997
Lancet. 2017 Jan 21;389(10066):299-311
pubmed: 27574741
Int J Clin Exp Pathol. 2015 Dec 01;8(12):15887-94
pubmed: 26884860
Cancer Discov. 2014 Apr;4(4):452-65
pubmed: 24444711
PLoS One. 2017 Aug 10;12(8):e0182562
pubmed: 28796802
Cell Rep. 2017 Feb 21;18(8):1958-1969
pubmed: 28228261
Sci Rep. 2017 Oct 30;7(1):14300
pubmed: 29085026
Tumour Biol. 2013 Jun;34(3):1813-8
pubmed: 23475633
PLoS One. 2012;7(7):e40597
pubmed: 22792380
Cancer Res. 2016 Feb 15;76(4):866-76
pubmed: 26744530
Cancer Res. 2010 Jul 1;70(13):5368-78
pubmed: 20551051
Clin Cancer Res. 2007 Mar 15;13(6):1892-902
pubmed: 17363546
Am J Respir Crit Care Med. 2016 Dec 15;194(12):1494-1505
pubmed: 27373892
J Exp Med. 2018 Apr 2;215(4):1205-1225
pubmed: 29472497

Auteurs

Mohamed I Saad (MI)

Centre for Innate Immunity and Infectious Diseases, Hudson Institute of Medical Research, Clayton, Vic., Australia.
Department of Molecular and Translational Sciences, Faculty of Medicine, Nursing and Health Sciences, Monash University, Clayton, Vic., Australia.
ORCID: 0000-0002-4855-2360

Sultan Alhayyani (S)

Centre for Innate Immunity and Infectious Diseases, Hudson Institute of Medical Research, Clayton, Vic., Australia.
Department of Molecular and Translational Sciences, Faculty of Medicine, Nursing and Health Sciences, Monash University, Clayton, Vic., Australia.

Louise McLeod (L)

Centre for Innate Immunity and Infectious Diseases, Hudson Institute of Medical Research, Clayton, Vic., Australia.
Department of Molecular and Translational Sciences, Faculty of Medicine, Nursing and Health Sciences, Monash University, Clayton, Vic., Australia.

Liang Yu (L)

Centre for Innate Immunity and Infectious Diseases, Hudson Institute of Medical Research, Clayton, Vic., Australia.
Department of Molecular and Translational Sciences, Faculty of Medicine, Nursing and Health Sciences, Monash University, Clayton, Vic., Australia.

Mohammad Alanazi (M)

Centre for Innate Immunity and Infectious Diseases, Hudson Institute of Medical Research, Clayton, Vic., Australia.
Department of Molecular and Translational Sciences, Faculty of Medicine, Nursing and Health Sciences, Monash University, Clayton, Vic., Australia.

Virginie Deswaerte (V)

Centre for Innate Immunity and Infectious Diseases, Hudson Institute of Medical Research, Clayton, Vic., Australia.
Department of Molecular and Translational Sciences, Faculty of Medicine, Nursing and Health Sciences, Monash University, Clayton, Vic., Australia.

Ke Tang (K)

Centre for Innate Immunity and Infectious Diseases, Hudson Institute of Medical Research, Clayton, Vic., Australia.
Department of Molecular and Translational Sciences, Faculty of Medicine, Nursing and Health Sciences, Monash University, Clayton, Vic., Australia.

Thierry Jarde (T)

Cancer Program, Monash Biomedicine Discovery Institute, Clayton, Vic., Australia.
Department of Anatomy and Developmental Biology, Monash University, Clayton, Vic., Australia.
Centre for Cancer Research, Hudson Institute of Medical Research, Clayton, Vic., Australia.

Julian A Smith (JA)

Department of Surgery, School of Clinical Sciences at Monash Health, Monash University, Clayton, Vic., Australia.
Department of Cardiothoracic Surgery, Monash Health, Clayton, Vic., Australia.

Zdenka Prodanovic (Z)

Monash Biobank, Monash Health, Clayton, Vic., Australia.

Michelle D Tate (MD)

Centre for Innate Immunity and Infectious Diseases, Hudson Institute of Medical Research, Clayton, Vic., Australia.
Department of Molecular and Translational Sciences, Faculty of Medicine, Nursing and Health Sciences, Monash University, Clayton, Vic., Australia.

Jesse J Balic (JJ)

Centre for Innate Immunity and Infectious Diseases, Hudson Institute of Medical Research, Clayton, Vic., Australia.
Department of Molecular and Translational Sciences, Faculty of Medicine, Nursing and Health Sciences, Monash University, Clayton, Vic., Australia.

D Neil Watkins (DN)

The Kinghorn Cancer Centre, Garvan Institute of Medical Research, Darlinghurst, NSW, Australia.

Jason E Cain (JE)

Department of Molecular and Translational Sciences, Faculty of Medicine, Nursing and Health Sciences, Monash University, Clayton, Vic., Australia.
Centre for Cancer Research, Hudson Institute of Medical Research, Clayton, Vic., Australia.

Steven Bozinovski (S)

School of Health and Biomedical Sciences, RMIT University, Bundoora, Vic., Australia.

Elizabeth Algar (E)

Centre for Cancer Research, Hudson Institute of Medical Research, Clayton, Vic., Australia.
Genetics and Molecular Pathology Laboratory, Monash Health, Clayton, Vic., Australia.

Tomohiro Kohmoto (T)

Department of Human Genetics, Tokushima University Graduate School of Medicine, Tokushima, Japan.
Division of Molecular Genetics, Aichi Cancer Center Research Institute, Nagoya, Japan.

Hiromichi Ebi (H)

Division of Molecular Therapeutics, Aichi Cancer Center Research Institute, Nagoya, Japan.
Division of Advanced Cancer Therapeutics, Nagoya University Graduate School of Medicine, Nagoya, Japan.

Walter Ferlin (W)

NovImmune SA, Geneva, Switzerland.

Christoph Garbers (C)

Department of Pathology, Medical Faculty, Otto-von-Guericke University, Magdeburg, Germany.

Saleela Ruwanpura (S)

Centre for Innate Immunity and Infectious Diseases, Hudson Institute of Medical Research, Clayton, Vic., Australia.
Department of Molecular and Translational Sciences, Faculty of Medicine, Nursing and Health Sciences, Monash University, Clayton, Vic., Australia.

Irit Sagi (I)

Department of Biological Regulation, Weizmann Institute of Science, Rehovot, Israel.

Stefan Rose-John (S)

Institute of Biochemistry, Christian-Albrechts-University, Kiel, Germany.

Brendan J Jenkins (BJ)

Centre for Innate Immunity and Infectious Diseases, Hudson Institute of Medical Research, Clayton, Vic., Australia brendan.jenkins@hudson.org.au.
Department of Molecular and Translational Sciences, Faculty of Medicine, Nursing and Health Sciences, Monash University, Clayton, Vic., Australia.
ORCID: 0000-0002-7552-4656

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female

Evaluation of Low-Value Services Across Major Medicare Advantage Insurers and Traditional Medicare.

Ciara Duggan, Adam L Beckman, Ishani Ganguli et al.
1.00
Humans United States Aged Cross-Sectional Studies Medicare Part C

Effectiveness of Virtual Yoga for Chronic Low Back Pain: A Randomized Clinical Trial.

Hallie Tankha, Devyn Gaskins, Amanda Shallcross et al.
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH

questionsmedicales.fr › Acides aminés, peptides et protéines › Protéines › Glycoprotéines › Protéines ADAM › Protéine ADAM17 › ADAM17 selectively activates the IL-6...
questionsmedicales.fr › Eucaryotes › Animaux › ADAM17 selectively activates the IL-6...
questionsmedicales.fr › Cellules › Cellules cultivées › Cellules cancéreuses en culture › Lignée cellulaire tumorale › ADAM17 selectively activates the IL-6...
questionsmedicales.fr › Phénomènes génétiques › Génotype › ADAM17 selectively activates the IL-6...
questionsmedicales.fr › Eucaryotes › Animaux › Chordés › Vertébrés › Mammifères › Eutheria › Primates › Haplorhini › Catarrhini › Hominidae › Humains › ADAM17 selectively activates the IL-6...
questionsmedicales.fr › Maladies de l'appareil respiratoire › Tumeurs de l'appareil respiratoire › Tumeurs du poumon › ADAM17 selectively activates the IL-6...
questionsmedicales.fr › Eucaryotes › Animaux › Chordés › Vertébrés › Mammifères › Eutheria › Rodentia › Muridae › Murinae › Souris › ADAM17 selectively activates the IL-6...
questionsmedicales.fr › Acides aminés, peptides et protéines › Protéines › Protéines et peptides de signalisation intracellulaire › Protein-Serine-Threonine Kinases › Mitogen-Activated Protein Kinases › Extracellular Signal-Regulated MAP Kinases › Mitogen-Activated Protein Kinase 1 › ADAM17 selectively activates the IL-6...
questionsmedicales.fr › Acides aminés, peptides et protéines › Protéines › Protéines et peptides de signalisation intracellulaire › Protein-Serine-Threonine Kinases › Mitogen-Activated Protein Kinases › Extracellular Signal-Regulated MAP Kinases › Mitogen-Activated Protein Kinase 3 › ADAM17 selectively activates the IL-6...
questionsmedicales.fr › Phénomènes génétiques › Variation génétique › Mutation › ADAM17 selectively activates the IL-6...
questionsmedicales.fr › Métabolisme › Phosphorylation › ADAM17 selectively activates the IL-6...
questionsmedicales.fr › Acides aminés, peptides et protéines › Protéines › Protéines tumorales › Protéines oncogènes › Protéines proto-oncogènes › Protéines proto-oncogènes p21(ras) › ADAM17 selectively activates the IL-6...
questionsmedicales.fr › Acides aminés, peptides et protéines › Protéines › Protéines membranaires › Récepteurs de surface cellulaire › Récepteurs immunologiques › Récepteurs aux cytokines › Récepteurs aux interleukines › Récepteurs à l'interleukine-6 › ADAM17 selectively activates the IL-6...
questionsmedicales.fr › Phénomènes physiologiques cellulaires › Transduction du signal › ADAM17 selectively activates the IL-6...
questionsmedicales.fr › Acides aminés, peptides et protéines › Protéines › Protéines et peptides de signalisation intracellulaire › Protein-Serine-Threonine Kinases › Mitogen-Activated Protein Kinases › p38 Mitogen-Activated Protein Kinases › ADAM17 selectively activates the IL-6...